Management of High-Risk Pulmonary Embolism with Tissue Plasminogen Activator

Classification and Risk Stratification

The European Society of Cardiology recommends classifying pulmonary embolism (PE) into high-risk, intermediate-risk, and low-risk categories based on hemodynamic instability and right ventricular dysfunction 1, 3
High-risk PE is characterized by hemodynamic instability, hypotension, or shock, and is associated with a high mortality rate 3
Intermediate-risk PE is hemodynamically stable but with right ventricular dysfunction and/or myocardial injury, and has a moderate mortality rate 1
Low-risk PE is hemodynamically stable without evidence of right ventricular dysfunction, and has a low mortality rate 1

The European Heart Society recommends systemic thrombolytic therapy with tissue plasminogen activator (tPA) for patients with high-risk PE characterized by hemodynamic instability, particularly hypotension or shock 1, 2
tPA is also indicated for patients with massive PE who are hypotensive or in shock 4, 5
Rescue therapy with tPA may be considered in patients with hemodynamic deterioration despite anticoagulation 1, 2

The standard dosing regimen for tPA is 100 mg infused over 2 hours, although an alternative regimen of 0.6 mg/kg over 15 minutes may be used 5, 6
Systemic intravenous administration is preferred, and direct local infusion via pulmonary artery catheter offers no advantages over systemic administration 4, 6

tPA rapidly resolves thromboembolic obstruction with beneficial hemodynamic effects, producing a 12% decrease in vascular obstruction within 2 hours and a 30% reduction in mean pulmonary arterial pressure 5, 6, 7
Approximately 92% of patients respond to thrombolysis with clinical and echocardiographic improvement within 36 hours 5, 7

Major bleeding occurs in approximately 13% of patients, and intracranial/fatal hemorrhage occurs in approximately 1.8-2% of patients 5, 7
Absolute contraindications to tPA include recent hemorrhage, recent stroke, and current gastrointestinal hemorrhage 4, 8
Relative contraindications include peptic ulcer disease, surgery within the preceding 7 days, prolonged cardiopulmonary resuscitation, and pregnancy (particularly within 6 hours of delivery or early postpartum) 4, 8

Thrombolysis may be appropriate for massive PE during pregnancy, but should be avoided within 6 hours of delivery or in early postpartum period due to high bleeding risk 4
Surgical pulmonary embolectomy may be considered for patients with high-risk PE in whom thrombolysis is contraindicated or has failed 1, 2